See more : Mooreast Holdings Ltd. (1V3.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Biomerica, Inc. (BMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biomerica, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Value HR Co.,Ltd. (6078.T) Income Statement Analysis – Financial Results
- Zhibao Technology Inc. Class A Ordinary Shares (ZBAO) Income Statement Analysis – Financial Results
- STRATA Skin Sciences, Inc. (SSKN) Income Statement Analysis – Financial Results
- Ashapura Minechem Limited (ASHAPURMIN.NS) Income Statement Analysis – Financial Results
- Nuveen California Select Tax-Free Income Portfolio (NXC) Income Statement Analysis – Financial Results
Biomerica, Inc. (BMRA)
About Biomerica, Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.42M | 5.34M | 18.87M | 7.20M | 6.69M | 5.20M | 5.56M | 5.79M | 5.14M | 4.96M | 5.12M | 6.47M | 6.08M | 4.90M | 5.08M | 4.93M | 4.93M | 5.75M | 7.18M | 9.27M | 9.17M | 9.06M | 8.60M | 8.94M | 8.03M | 8.70M | 9.40M | 9.20M | 9.50M | 9.20M | 8.30M | 8.00M | 7.80M | 10.40M | 8.20M | 1.20M | 1.40M | 1.90M | 1.70M |
| Cost of Revenue | 4.80M | 4.89M | 15.89M | 6.70M | 4.91M | 3.91M | 3.81M | 3.77M | 3.62M | 3.42M | 3.45M | 4.05M | 3.78M | 3.37M | 3.51M | 2.96M | 2.79M | 3.50M | 4.78M | 6.19M | 6.25M | 6.16M | 6.06M | 6.13M | 5.40M | 5.10M | 5.30M | 5.20M | 5.10M | 4.80M | 4.30M | 4.80M | 4.80M | 6.70M | 4.00M | 800.00K | 1.00M | 800.00K | 1.20M |
| Gross Profit | 611.00K | 446.00K | 2.98M | 496.98K | 1.78M | 1.29M | 1.75M | 2.02M | 1.52M | 1.54M | 1.67M | 2.43M | 2.30M | 1.53M | 1.56M | 1.97M | 2.14M | 2.25M | 2.41M | 3.09M | 2.92M | 2.90M | 2.54M | 2.81M | 2.63M | 3.60M | 4.10M | 4.00M | 4.40M | 4.40M | 4.00M | 3.20M | 3.00M | 3.70M | 4.20M | 400.00K | 400.00K | 1.10M | 500.00K |
| Gross Profit Ratio | 11.28% | 8.35% | 15.78% | 6.90% | 26.62% | 24.84% | 31.53% | 34.91% | 29.65% | 31.07% | 32.60% | 37.51% | 37.78% | 31.14% | 30.75% | 39.92% | 43.35% | 39.07% | 33.48% | 33.27% | 31.81% | 31.99% | 29.49% | 31.43% | 32.75% | 41.38% | 43.62% | 43.48% | 46.32% | 47.83% | 48.19% | 40.00% | 38.46% | 35.58% | 51.22% | 33.33% | 28.57% | 57.89% | 29.41% |
| Research & Development | 1.49M | 1.58M | 1.81M | 2.41M | 1.91M | 1.68M | 1.40M | 1.13M | 780.33K | 733.64K | 589.87K | 459.09K | 347.13K | 420.57K | 455.17K | 278.31K | 259.09K | 256.10K | 239.00K | 274.29K | 273.98K | 262.84K | 159.76K | 322.12K | 898.12K | 500.00K | 600.00K | 300.00K | 300.00K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.61K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.49M | 6.09M | 5.70M | 4.61M | 2.27M | 2.03M | 1.84M | 1.85M | 1.57M | 1.48M | 1.53M | 1.45M | 1.45M | 1.24M | 1.47M | 1.44M | 1.37M | 1.47M | 2.26M | 3.05M | 2.96M | 2.85M | 2.84M | 3.17M | 5.70M | 3.10M | 3.10M | 2.90M | 3.10M | 3.30M | 3.40M | 3.00M | 3.60M | 4.80M | 3.70M | 1.20M | 1.90M | 2.30M | 2.40M |
| Other Expenses | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.01K | 2.26K | 3.13K | 50.00 | 0.00 | 290.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.98M | 7.67M | 7.51M | 7.02M | 4.18M | 3.70M | 3.24M | 2.98M | 2.35M | 2.21M | 2.12M | 1.91M | 1.79M | 1.66M | 1.93M | 1.72M | 1.63M | 1.72M | 2.50M | 3.32M | 3.23M | 3.11M | 3.00M | 3.49M | 6.82M | 3.90M | 3.90M | 3.40M | 3.70M | 4.00M | 3.80M | 3.50M | 4.40M | 5.60M | 4.20M | 1.30M | 2.00M | 2.40M | 2.60M |
| Cost & Expenses | 11.78M | 12.56M | 23.41M | 13.72M | 9.10M | 7.61M | 7.05M | 6.75M | 5.97M | 5.63M | 5.57M | 5.96M | 5.58M | 5.03M | 5.44M | 4.69M | 4.42M | 5.23M | 7.28M | 9.51M | 9.48M | 9.27M | 9.06M | 9.62M | 12.22M | 9.00M | 9.20M | 8.60M | 8.80M | 8.80M | 8.10M | 8.30M | 9.20M | 12.30M | 8.20M | 2.10M | 3.00M | 3.20M | 3.80M |
| Interest Income | 431.00K | 133.00K | 26.64K | 66.86K | 71.19K | 44.01K | 47.76K | 46.35K | 24.12K | 21.91K | 17.18K | 10.71K | 8.35K | 7.37K | 14.71K | 29.87K | 33.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 26.64K | 367.00 | 9.00 | 47.00 | 37.00 | 282.00 | 167.00 | 0.00 | 142.00 | 302.00 | 1.59K | 5.83K | 12.32K | 27.52K | 49.54K | 35.05K | 0.00 | 0.00 | 0.00 | 0.00 | 40.37K | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 374.00K | 351.00K | 594.82K | 375.86K | 398.63K | 162.91K | 186.60K | 219.22K | 232.42K | 253.28K | 207.03K | 216.71K | 180.12K | 147.81K | 114.01K | 88.65K | 65.83K | 56.74K | 122.05K | 159.32K | 144.16K | 116.55K | 192.42K | 208.99K | 222.33K | 300.00K | 200.00K | 200.00K | 300.00K | 400.00K | 400.00K | 500.00K | 800.00K | 800.00K | 500.00K | 100.00K | 100.00K | 100.00K | 200.00K |
| EBITDA | -5.99M | -6.74M | -3.94M | -7.06M | -2.27M | -2.21M | -1.25M | -689.34K | -563.57K | -393.15K | -219.25K | 741.48K | 795.16K | 313.09K | -218.12K | 383.36K | 1.72M | 537.49K | 24.96K | -75.45K | -171.98K | -93.34K | -273.00K | -408.86K | -3.97M | 0.00 | 400.00K | 800.00K | 1.00M | 800.00K | 600.00K | 200.00K | -600.00K | -1.10M | 800.00K | -800.00K | -1.50M | -1.20M | -1.90M |
| EBITDA Ratio | -110.67% | -128.71% | -20.73% | -84.45% | -28.88% | -42.42% | -22.42% | -11.90% | -10.96% | -7.92% | -4.28% | 11.45% | 11.27% | 6.39% | -4.65% | 7.42% | -11.66% | 9.35% | -0.29% | -1.20% | -2.74% | -1.80% | -2.80% | -5.84% | -50.86% | -3.45% | 2.13% | 7.61% | 10.53% | 8.70% | 7.23% | 1.25% | -8.97% | -10.58% | 9.76% | -75.00% | -178.57% | -57.89% | -105.88% |
| Operating Income | -6.37M | -7.22M | -4.53M | -6.52M | -2.40M | -2.41M | -1.48M | -954.63K | -826.95K | -670.60K | -446.59K | 514.01K | 505.00K | -132.26K | -364.52K | 247.66K | 509.49K | 520.79K | -97.09K | -234.76K | -316.14K | -209.88K | -465.42K | -683.58K | -4.19M | -300.00K | 200.00K | 600.00K | 700.00K | 400.00K | 200.00K | -300.00K | -1.40M | -1.90M | 300.00K | -900.00K | -1.60M | -1.30M | -2.10M |
| Operating Income Ratio | -117.58% | -135.29% | -24.03% | -90.60% | -35.90% | -46.39% | -26.63% | -16.48% | -16.09% | -13.51% | -8.72% | 7.94% | 8.30% | -2.70% | -7.18% | 5.02% | 10.34% | 9.06% | -1.35% | -2.53% | -3.45% | -2.32% | -5.41% | -7.65% | -52.16% | -3.45% | 2.13% | 6.52% | 7.37% | 4.35% | 2.41% | -3.75% | -17.95% | -18.27% | 3.66% | -75.00% | -114.29% | -68.42% | -123.53% |
| Total Other Income/Expenses | 431.00K | 134.00K | 26.64K | 66.50K | 71.18K | 43.97K | 47.73K | 46.07K | 30.97K | 24.16K | 20.17K | 10.46K | 108.45K | 291.71K | 20.07K | 19.52K | 1.13M | 4.99K | 785.00 | 215.24K | 18.91K | -11.77K | -99.19K | 103.21K | 301.56K | 300.00K | -200.00K | 100.00K | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K | 900.00K | -300.00K | 100.00K | 1.00M | -100.00K | -100.00K |
| Income Before Tax | -5.94M | -7.09M | -4.51M | -6.46M | -2.33M | -2.37M | -1.43M | -908.56K | -795.99K | -646.43K | -426.42K | 524.46K | 613.45K | 159.45K | -344.46K | 267.18K | 1.64M | 525.78K | 155.37K | -19.53K | -297.23K | -221.65K | -564.61K | -576.49K | -3.89M | 0.00 | 400.00K | 700.00K | 0.00 | 0.00 | 300.00K | -200.00K | -1.30M | -1.00M | 0.00 | -800.00K | -600.00K | -1.40M | -2.20M |
| Income Before Tax Ratio | -109.62% | -132.78% | -23.88% | -89.68% | -34.84% | -45.55% | -25.77% | -15.69% | -15.49% | -13.03% | -8.33% | 8.10% | 10.09% | 3.25% | -6.79% | 5.41% | 33.35% | 9.15% | 2.16% | -0.21% | -3.24% | -2.45% | -6.57% | -6.45% | -48.40% | 0.00% | 4.26% | 7.61% | 0.00% | 0.00% | 3.61% | -2.50% | -16.67% | -9.62% | 0.00% | -66.67% | -42.86% | -73.68% | -129.41% |
| Income Tax Expense | 42.00K | 51.00K | 23.72K | 13.06K | 7.39K | 24.24K | 31.80K | 46.64K | 703.80K | -315.02K | -210.76K | -12.49K | 65.01K | 2.00K | -13.00K | -87.00K | -67.00K | 16.77K | 1.60K | 1.94K | 1.82K | 2.22K | 2.06K | 2.40K | 2.40K | -200.00K | 100.00K | 200.00K | 300.00K | 300.00K | 300.00K | 100.00K | -500.00K | 200.00K | 600.00K | 0.00 | -1.20M | 0.00 | -200.00K |
| Net Income | -5.98M | -7.14M | -4.53M | -6.47M | -2.34M | -2.39M | -1.47M | -908.56K | -1.50M | -331.41K | -215.66K | 536.96K | 548.44K | 157.45K | -331.46K | 354.18K | 1.71M | 536.88K | 230.27K | 162.26K | -223.20K | -223.87K | -420.74K | -2.67M | -3.89M | -100.00K | 100.00K | 400.00K | 400.00K | 100.00K | 0.00 | -400.00K | -900.00K | -1.20M | -600.00K | -900.00K | -400.00K | -1.30M | -1.90M |
| Net Income Ratio | -110.40% | -133.73% | -24.01% | -89.86% | -34.95% | -46.01% | -26.34% | -15.69% | -29.18% | -6.68% | -4.21% | 8.30% | 9.02% | 3.21% | -6.53% | 7.18% | 34.71% | 9.34% | 3.20% | 1.75% | -2.43% | -2.47% | -4.89% | -29.89% | -48.43% | -1.15% | 1.06% | 4.35% | 4.21% | 1.09% | 0.00% | -5.00% | -11.54% | -11.54% | -7.32% | -75.00% | -28.57% | -68.42% | -111.76% |
| EPS | -0.36 | -0.50 | -0.36 | -0.54 | -0.23 | -0.26 | -0.17 | -0.11 | -0.20 | -0.04 | -0.03 | 0.08 | 0.08 | 0.02 | -0.05 | 0.05 | 0.28 | 0.09 | 0.04 | 0.03 | -0.04 | -0.04 | -0.08 | -0.56 | -0.86 | -0.03 | 0.04 | 0.12 | 0.12 | 0.03 | 0.02 | -0.14 | -0.30 | -0.40 | -0.18 | -0.30 | -0.14 | -0.44 | -0.66 |
| EPS Diluted | -0.36 | -0.50 | -0.36 | -0.54 | -0.23 | -0.26 | -0.17 | -0.11 | -0.20 | -0.04 | -0.03 | 0.07 | 0.08 | 0.02 | -0.05 | 0.05 | 0.25 | 0.08 | 0.03 | 0.03 | -0.04 | -0.04 | -0.08 | -0.56 | -0.86 | -0.03 | 0.03 | 0.10 | 0.12 | 0.03 | 0.02 | -0.14 | -0.30 | -0.40 | -0.18 | -0.30 | -0.14 | -0.44 | -0.66 |
| Weighted Avg Shares Out | 16.82M | 14.15M | 12.67M | 11.93M | 10.17M | 9.21M | 8.57M | 8.26M | 7.50M | 7.55M | 7.19M | 7.02M | 6.89M | 6.67M | 6.65M | 6.62M | 6.13M | 5.93M | 5.76M | 5.75M | 5.74M | 5.30M | 5.10M | 4.81M | 4.54M | 4.00M | 4.00M | 3.86M | 3.59M | 3.33M | 3.33M | 2.86M | 3.00M | 3.00M | 3.33M | 3.00M | 2.86M | 2.95M | 2.88M |
| Weighted Avg Shares Out (Dil) | 16.82M | 14.15M | 12.67M | 11.93M | 10.17M | 9.21M | 8.57M | 8.33M | 7.63M | 7.55M | 7.37M | 7.45M | 7.11M | 6.70M | 6.65M | 7.01M | 6.98M | 6.51M | 6.22M | 6.62M | 5.74M | 5.30M | 5.10M | 4.81M | 4.54M | 4.00M | 4.00M | 3.87M | 3.59M | 3.33M | 3.33M | 2.86M | 3.00M | 3.00M | 3.33M | 3.00M | 2.86M | 2.95M | 2.88M |
Biomerica Reports Third Quarter 2024 Financial Results
IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2024 ended February 29, 2024.
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies...
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience...
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to...
Biomerica Reports Second Quarter 2024 Financial Results
IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2024 ended November 30, 2023.
Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population
IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect™ Stool...
Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16
IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at...
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that several new Gastrointestinal (GI) groups have signed up and begun using the Company's revolutionary inFoods® IBS...
REPEAT - Biomerica Reports First Quarter 2024 Financial Results
Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024 vs the first fiscal quarter of 2023 Company believes current cash position, forecasted revenue growth and corporate strategy is expected to enable it to achieve profitability GAAP...
Biomerica Reports First Quarter 2024 Financial Results
Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024 vs the first fiscal quarter of 2023 Company believes current cash position, forecasted revenue growth and corporate strategy is expected to enable it to achieve profitability GAAP...
Source: https://incomestatements.info
Category: Stock Reports